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Abstract
Adoptive transfer of chimeric antigen receptor (CAR)-redirected T lymphocytes (CAR-T cells) 
has had less striking effects in solid tumors1–3 than in lymphoid malignancies4, 5. Although active 
tumor-mediated immunosuppression may play a role in limiting efficacy6, functional changes in T 
lymphocytes following their ex vivo manipulation may also account for cultured CAR-T cells’ 
reduced ability to penetrate stroma-rich solid tumors. We therefore studied the capacity of human 
in vitro-cultured CAR-T cells to degrade components of the extracellular matrix (ECM). In 
contrast to freshly isolated T lymphocytes, we found that in vitro-cultured T lymphocytes lack 
expression of the enzyme heparanase (HPSE) that degrades heparan sulphate proteoglycans, 
which are main components of ECM. We found that HPSE mRNA is down regulated in in vitro-
expanded T cells, which may be a consequence of p53 binding to the HPSE gene promoter. We 
therefore engineered CAR-T cells to express HPSE and showed improved capacity to degrade 
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ECM, which promoted tumor T-cell infiltration and antitumor activity. Employing this strategy 
may enhance the activity of CAR-T cells in individuals with stroma-rich solid tumors.
CAR-T cells in vitro-cultured consist mostly of memory and effector lymphocytes 
characterized by potent cytotoxic function1, 4, 7. However to exploit their effector function 
CAR-T cells must traffic to and accumulate in tumor sites. These properties involve a 
complex sequence of events that, beginning with the adhesion of T cells to endothelial cells 
followed by chemokine-chemokine receptor interactions, modulates their extravasation into 
antigen-rich tissues8–10. During this process, T lymphocytes actively degrade the main 
components of the subendothelial basement membrane and the extracellular matrix (ECM), 
including the heparan sulphate proteoglycans (HSPGs)11. ECM is an integral component of 
the stroma, therefore T cells attacking stroma-rich solid tumors must be able to degrade 
HSPGs in order to access tumor cells and exert antitumor effects.
The release of specific enzymes by T cells is fundamental to the degradation of ECM. One 
of these enzymes is heparanase (HPSE), which is the only known mammalian β-D-
endoglycosidase capable of cleaving the heparan sulphate chains of HSPGs9, 12–14. HPSE is 
first synthesized as a latent precursor protein of ~65kDa and then cleaved into two subunits 
of ~8 and ~50 kDa that heterodimerize to form the enzymatically active protein13. HPSE is 
produced in large amounts by activated CD4+ T lymphocytes, neutrophils, monocytes and B 
lymphocytes15–17. However, the exact contribution of HPSE in mediating the tumor 
infiltration of in vitro-cultured, tumor-specific T cells remains unexplored.
We first assessed whether ex vivo expanded human T cells are defective in their capacity to 
degrade ECM. Using a Matrigel™-based cell invasion assay, we compared the invasion 
capacity of freshly isolated resting T cells (FI-T), briefly activated T cells (BA-T) (24 hour 
activation with OKT3 and anti-CD28 Abs) and long-term ex vivo expanded T cells (LTE-T) 
(activation with OKT3 and anti-CD28 Abs and ex vivo culture for 12–14 days). Consistent 
with previously reported data in rodents12, BA-T showed superior invasion of ECM 
compared to FI-T (34% ± 8% vs. 23% ± 8%, respectively; p=0.05). Conversely, LTE-T had 
significantly reduced ability to degrade ECM (8% ± 6%) compared to both BA-T (p=0.01) 
and FI-T (p=0.022) (Fig. 1a). To dissect the mechanisms responsible for this observation we 
evaluated the expression and function of HPSE in each cell population. In accordance with 
the cell invasion assay, both CD4+ and CD8+ T cells from FI-T and BA-T retained the 
active form of HPSE (50 KDa), while the enzyme was lost in LTE-T by day 2 of culture 
(Fig. 1b,c). The loss of HPSE expression was not determined by the culture media or 
cytokines used for T-cell growth, since we observed similar results using either human AB 
serum or fetal bovine serum, and either IL-2, IL-7 or IL-15 as T-cell growth factors 
(Supplementary Fig. 1). We also found that the down regulation of HPSE expression in 
response to stimulation with OKT3 and anti-CD28 Abs and cytokines is observed in naive 
(CD45RA+), central-memory (CD45RO+CD62L+) and effector-memory 
(CD45RO+CD62L−) cells isolated from the peripheral blood suggesting that this is a general 
phenomenon and non T-cell subset specific (Supplementary Fig. 2). The absence of HPSE 
protein in LTE-T was associated with the down-regulation of the HPSE mRNA. As shown 
in Fig. 1d, HPSE mRNA decreased immediately after activation in both CD4+ and CD8+ T 
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cells compared to CD14+ monocytes (p<0.005 and p<0.031, respectively) and remained low 
over the following 14 days of culture. Re-stimulation of LTE-T with OKT3 and anti-CD28 
Abs on day 14 of culture did not induce re-expression of either the HPSE mRNA or protein 
(Fig. 1b,d). The lack of cellular HPSE in LTE-T was also confirmed by the absence of 
enzymatic activity in the culture supernatant. As shown in Fig. 1e, HPSE enzymatic activity 
was detected in supernatants collected within the first 72 hours after activation of FI-T. This 
detection can be attributed to enzyme accumulation in the culture media. However, the 
enzymatic activity returned to background levels 72 hours later (from 0.34 ± 0.2 U ml and 
0.45 ± 0.27 U ml to 0.22 ± 0.06 U ml for both for CD4+ and CD8+ T cells (Fig. 1e). This 
observation is in line with previous studies reporting that preformed HPSE protein is stored 
in an intracellular compartment and released as an early event in response to T-cell 
activation18. We found that HPSE is also absent in Epstein Barr Virus-specific cytotoxic T 
cells that are stimulated in vitro by antigen-presenting cells, suggesting that HPSE loss in 
LTE-T is not caused by a supra-physiological activation of these cells mediated by the 
OKT3 Ab (Supplementary Fig. 2)19. Previous studies showed that p53 mutated with loss of 
function in tumor cells is associated with over-expression of HPSE20. Since there is an 
accumulation of the full-length p53 protein in LTE-T20, 21, we found that the lack of HPSE 
mRNA expression in LTE-T may be due to the accumulation of the full-length p53 protein 
in LTE-T that binds to the HPSE gene promoter (Fig. 1f-h)(Supplementary Fig. 3). The 
immediate translational implication of these findings is that T cells in vitro-engineered and 
cultured for adoptive immunotherapy lacks HPSE expression when infused into the subjects 
and are thus impaired in their capacity to degrade components of ECM of the stroma. It is 
also important to note that the cleavage of HPSG chains by HPSE releases preformed stored 
chemokines into the stroma22, 23. Since chemokines also guide the migration of T cells 
towards their target cells within the tumor microenvironment, the lack of HPSE may further 
indirectly compromise the antitumor effects of T cells by reducing their migration.
We thus hypothesized that engineering LTE-T to express HPSE through retroviral gene 
transfer would improve their invasion capability. LTE-T transduced with the HPSE(I)GFP 
retroviral vector expressed GFP (Fig. 2a) and HPSE (Fig. 2b). HPSE expression remained 
high in transduced LTE-T starved from cytokines in culture for more than 10 days, 
suggesting a stable expression of the transgene (Fig. 2c). In functional assays, HPSE(I)GFP+ 
LTE-T better degraded ECM (48% ± 19%) than did control untransduced LTE-T (29% ± 
18%; p=0.025) (Fig. 2d). The addition of the HPSE-inhibitor Heparin H124, confirmed that 
the invasion of HPSE(I)GFP+ LTE-T is HPSE-specificity, as invasion was reduced from 
74% ± 14% in the absence of inhibitor to 29% ± 9% (p<0.01) in the presence of Heparin H1 
(Fig. 2e). We then assessed whether HPSE expression leading to improved cell invasion 
could be coupled with antitumor specificity. We used neuroblastoma (NB) as a cancer 
model, since this tumor has been targeted in a clinical trial with a CAR specific for the NB-
associated antigen GD2 with some clinical responses1. On day 14 of culture, CAR 
expression was 71% ± 14% and 56% ± 6% in LTE-T transduced with CAR and 
CAR(I)HPSE vectors, respectively (Fig. 3a). HPSE was detected only in LTE-T transduced 
with the CAR(I)HPSE vector (Fig. 3b). Both CAR+ and CAR(I)HPSE+ LTE-T lysed the 
GD2+ targets human NB cell line LAN-1 (71% ± 22% and 41% ± 16%, respectively, at a 
20:1 E:T ratio in a 51Cr-release assay)(p=ns), and the human NB cell line CHLA-255 (76% 
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± 7% and 55% ± 13%, respectively)(p=ns), while both showed negligible activity against 
the GD2− target Raji (<8%) (Fig. 3c). Control LTE-T lacking the CAR lysed none of these 
targets. The cytolytic activity was associated with a preserved Th1 cytokine profile as CAR+ 
and CAR(I)HPSE+ LTE-T released similar amounts of IFN-γ (927 ± 328 and 527 ± 320 pg 
ml ×106 cells, respectively; p=ns) and IL-2 (83 ± 6 and 61 ± 27 pg ml ×106 cells, 
respectively, p=ns) in response to stimulation with the GD2 antigen (Fig. 3d). In sharp 
contrast to their comparable cytolytic function, only CAR(I)HPSE+ LTE-T degraded ECM 
(66% ± 1%) compared to CAR+ or control LTE-T (13% ± 9% and 16% ± 10%, 
respectively) (p=0.004 and p<0.001) (Fig. 3e). To prove ex vivo that LTE-T co-expressing 
HPSE and CAR have increased antitumor activity in the presence of ECM, we plated LTE-T 
and tumor cells in a Matrigel™ cell invasion assay, in which LTE-T must degrade ECM to 
reach and eliminate the tumor targets. After 3 days of culture, both CAR+ and 
CAR(I)HPSE+ LTE-T eliminated LAN-1 tumor cells equally well in the absence of ECM 
(insert) (<3% GFP+ tumor cells) compared to control LTE-T (31% ± 6% GFP+ tumor cells) 
(Fig. 3f,g). By contrast, in the presence of ECM, CAR(I)HPSE+ LTE-T eliminated all but 
16% ± 8% of LAN-1 cells compared to 37% ± 12% in the presence of CAR+ LTE-T 
(p=0.001) (Fig. 3f,g). Control LTE-T did not show antitumor activity in any condition 
(either insert or ECM) (45% ± 9% GFP+ tumor cells). We obtained identical results with the 
NB line CHLA-255 (Supplementary Fig. 4). Thus, only LTE-T co-expressing HPSE and 
CAR show robust antitumor activity in the presence of ECM. The improved antitumor 
activity of CAR(I)HPSE+ LTE-T was achieved without causing detectable detrimental 
effects on T lymphocytes since these cells expanded in vitro, retained the same phenotype of 
CAR+ LTE-T and did not show increased activation-induced cell death in response to either 
OKT3 Ab, which binds CD3, or 1A7 anti-idiotype Ab, which causes cross-linking of the 
GD2-specific CAR1 (Supplementary Fig. 5).
To validate our findings in vivo, we first established xenograft models of NB by implanting 
NSG mice intraperitoneally (i.p.) with either CHLA-255 or LAN-1 NB cell lines in the 
presence of Matrigel™ to allow the formation of complex and structured tumors. We utilized 
the i.p. route to minimize confounding variables related to T-cell homing to the tumor, a 
known issue in NB xenograft models when the tumor is inoculated subcutaneously25. After 
10 days, mice received i.p. either control, CAR+ or CAR(I)HPSE+ LTE-T. As shown in Fig. 
4a, mice implanted with CHLA-255 tumor cells and treated with CAR(I)HPSE+ LTE-T had 
significantly improved survival by day 40 compared to mice treated with control LTE-T 
(p<0.001) or CAR+ LTE-T (p<0.007). Among treated mice, we found 6 of 22 infused with 
CAR+ LTE-T, and 18 of 26 infused with CAR(I)HPSE+ LTE-T macroscopically tumor free 
at the time we ended the observation by day 40 (p=0.008). We obtained similar results in 
mice engrafted with LAN-1 tumor cells. Mice infused with CAR(I)HPSE+ LTE-T had 
significantly improved survival compared to mice treated with control (p<0.0001) or CAR+ 
LTE-T at day 50 (p<0.039) (Fig. 4b and Supplementary Fig. 6). In another set of 
experiments, we euthanized mice on day 12–14 after T-cell infusion to measure tumor T-cell 
infiltration. Tumors collected from mice infused with CAR(I)HPSE+ LTE-T had greater T-
cell infiltration (4.6% ± 2.4%) compared to those treated with control (0.6% ± 0.5; p=0.029) 
or CAR+ LTE-T (0.1% ± 0.1; p=0.043) (Fig. 4c). Tumors collected from euthanized mice 
also showed a significant reduction in weight in recipients infused with CAR(I)HPSE+ LTE-
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T compared to control (0.8 g ± 0.6 g vs. 3.3 g ± 2.4 g) (p=0.039), and when compared to 
mice infused with CAR+ LTE-T (0.8 g ± 0.6 g vs. 2.5 g ± 2 g) although this difference was 
not statistically significant (p=0.093) (Fig. 4d). Since NB cell lines require Matrigel™ to 
form complex and structured tumors when infused i.p., we also implemented a third NB 
model in which CHLA-255 tumor cells labeled with firefly luciferase were implanted in the 
kidney of NSG mice without using Matrigel™ 26, and CAR+ LTE-T and CAR(I)HPSE+ LTE 
were infused intravenously (i.v). Tumor sections from mice infused i.v. with CAR(I)HPSE+ 
LTE-T showed enhanced infiltration of CD3+ T cells compared to CAR+ LTE-T (cell 
numbers 357 ± 72 and 173 ± 32, respectively; p=0.028) (Fig. 4e,f,g). Long-term observation 
of infused mice also showed improved survival of recipients treated with CAR(I)HPSE+ 
LTE-T by day 50 (p<0.005) (Fig. 4f and Supplementary Fig. 6).
Finally, we extended our observation to CAR+ LTE-T targeting the solid tumor-associated 
antigen chondroitin sulphate proteoglycan 4 (CSPG4)27 in an aggressive melanoma model, 
suggesting that the positive effect of HPSE in CAR-T cells can be exported to other targeted 
antigens and solid tumors (Supplementary Fig. 7). In contrast, the co-expression of HPSE in 
LTE-T redirected with a CD19-specific CAR did not appear to play a role in B-lymphoid 
malignancies, which are generally stroma-poor compared to solid tumors (Supplementary 
Fig. 8).
Under physiological conditions, HPSE expression by T cells is regulated to avoid tissue 
damage from T-cell extravasation into non-pathologic tissues16, 17, 28, 29. To rule out 
concerns about non-specific infiltration of normal tissues, such as lung or liver, by HPSE-
engineered LTE-T, we evaluated in vivo T-cell bio-distribution. For these experiments, we 
labeled CAR(I)HPSE+ and CAR+ LTE-T with the vector encoding GFP and firefly 
luciferase and infused them via tail injection. T-cell bio-distribution evaluated by in vivo 
imaging at different time points after T-cell inoculation and immunohistochemistry at early 
and late passages did not show differences between the two groups of mice, suggesting no 
preferential accumulation in lung or liver of HPSE-engineered LTE-T (Supplementary Fig. 
9a,b).
In conclusion, HPSE deficiency in in vitro-engineered and cultured tumor-specific LTE-T 
may limit their antitumor activity in stroma-rich solid tumors. Other enzymes such as 
metallo-proteases are also involved in modifications of ECM components and may 
compensate HPSE deficiency30. However, we found that some metallo-proteases are also 
downregulated upon TCR activation and cytokine exposure (Supplementary Fig. 10a,b). We 
thus suggest that inducing expression of HPSE in LET-T co-expressing a tumor-specific 
CAR improves their capacity to degrade ECM without compromising their viability, 
expansion or effector function and promotes increased antitumor activity. The proposed 
strategy may enhance the antitumor activity of CAR-redirected T cells in subjects with 
stroma-rich solid tumors.
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293T, DU-145 and CHLA-255 cell lines were cultured in IMDM (Gibco, Invitrogen™, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, HyClone, Thermo 
Scientific, Pittsburgh, PA) and 2 mM GlutaMax (Invitrogen, Carlsbad, CA). MCF-7, Raji, 
K562, LAN-1, Daudi and SENMA cells were cultured in RPMI1640 (HyClone) 
supplemented with 10% FBS and 2 mM GlutaMax. A549 cells were cultured in DMEM 
(GIBCO) supplemented with 10% fetal bovine serum and 2 mM GlutaMax Cells were 
maintained in a humidified atmosphere containing 5% CO2 at 37°C. Tumor cell lines 
MCF-7, CHLA-255, A549 and DU-145 produced HPSE. All cell lines were routinely tested 
for mycoplasma and for surface expression of target antigens. Furthermore, all cell lines 
were authenticated except for CHLA 255 that was established from a neuroblastoma subject 
and SENMA that was established in our laboratory from a melanoma subject31. However, 
we routinely verified that this line retained the surface expression of the target antigens.
Isolation and culture of primary human T lymphocytes
Peripheral blood mononuclear cells (PBMC) were isolated from samples obtained from 
healthy volunteers from the protocol entitled “Humoral and cellular immune responses to 
tumor-associated antigens (TAA) – healthy blood and skin donors” which is being 
conducted after approval by the Institutional Review Board of Baylor College of Medicine, 
or anonymous buffy coats of healthy donors (Gulf Coast Regional Blood Center, Houston, 
TX) using Lymphoprep™ density separation (Fresenius Kabi Norge, Oslo, Norway). 
Monocytes were obtained from PBMC by positive magnetic selection with CD14 
microbeads (Miltenyi Biotec, Auburn, CA). CD8+ and CD4+ T cells were also obtained 
from PBMC by negative magnetic selection (Miltenyi Biotec). In selected experiments, 
naive (CD45RA+), central-memory (CD45RO+CD62L+) and effector-memory 
(CD45RO+CD62L−) T cells were also separated from PBMC by CD45RA depletion and 
CD62L positive paramagnetic selection (Miltenyi Biotec). T lymphocytes were activated 
with immobilized OKT3 (1 μg ml) and anti-CD28 (#555725, Becton Dickinson Biosciences, 
Franklin Lakes, NJ) (1 μg ml) antibodies (Abs) and then expanded in complete medium 
containing 45% RPMI1640 and 45% Click’s medium (Irvine Scientific, Santa Ana, CA, 
USA) supplemented with 10% FBS and 2 mM GlutaMAX. Cells were fed twice a week 
with recombinant interleukin-2 (IL-2) (50 U mL) (Chiron Therapeutics, Emeryville, CA). 
We defined as FI-T: freshly isolated resting T cells from peripheral blood that comprise 
naive, effector-memory and central-memory T cells; BA-T: briefly activated T cells that 
result from incubation of FI-T with OKT3 and anti-CD28 Abs for 24 hours; LTE-T: long 
term ex vivo expanded T cells that result from BA-T cultured ex vivo for 12–14 days and 
consist mostly of central-memory and effector-memory T cells. At day 14 of culture, LTE-T 
cells were reactivated with OKT3 and anti-CD28 Abs and cultured for additional 24 hours. 
For the experiments in which we compared the invasion capacity of FI-T vs. BA-T vs. LTE-
T side by side, we obtained 3 separated blood draws at different time points from the donors 
to make in LTE-T, BA-T and FI-T to be able to run all the samples in parallel in the 
invasion assay.
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The capacity of each cell subset to degrade ECM was examined in vitro using the BioCoat™ 
Matrigel™ Invasion assay (Becton Dickinson Biosciences) following the manufacturer’s 
instructions. Five percent FBS was used as a chemoattactant in the low chamber. All 
experiments were performed in duplicate. Data are expressed as the percentage of invasion 
through the Matrigel™ and the membrane relative to the migration through the control 
membrane (8 μm polyethylene terephthalate membrane pores). The percentage of invasion 
was calculated as follows: (mean of cells invading through the Matrigel™ chamber 
membrane/mean of cells migrating through the control insert membrane) × 100. In specific 
experiments, we simultaneously evaluated the invasion and antitumor activity of LTE-T. 
Briefly, we used the BioCoat™ Matrigel™ Invasion assay and plated LAN-1-GFP+ or 
CHLA-255-GFP+ cells (1.4 × 105) in the bottom of a 24-well plate and LTE-T (2.5 × 105 
cells) in the upper chamber/insert. Chambers and inserts were removed 24 hours later. After 
three days of culture cells were then collected from the lower chamber and quantified by 
flow cytometry to identify tumor cells and T cells, respectively.
Western blot
Twenty μg of proteins were resolved by SDS-PAGE and transferred to polyvinylidene 
difluoride membranes (Bio-Rad, Hercules, CA). The Abs and dilutions used in these 
experiments were as follows: mouse anti-human HPA1-HPSE (1:100 and 1:6500 dilution, 
clone HP130 and HP3-17, respectively) (InSight Biopharmaceuticals Ltd, Rehovot, Israel) 
that recognizes both the 65kDa precursor and the 50kDa active form of HPSE-1, rabbit anti-
human HPA1 polyclonal (1:4000 dilution) (#CLANT155, Cedarlane, Burlington, NC), 
mouse anti-human p53 (1:200 dilution, clone DO-1) (Santa Cruz Biotechnology, Santa 
Cruz, CA) that recognizes the full-length p53 protein, mouse anti-human β-actin (1:10000 
dilution, clone C4) (Santa Cruz Biotechnology) and horseradish peroxidase conjugated 
secondary Abs (1:5000 dilution, goat anti-mouse #sc-2005 and goat anti-rabbit #sc-2004) 
(Santa Cruz Biotechnology). Blots were then incubated with SuperSignal West Femto 
Maximum Sensitivity Substrate (Thermo Scientific).
Immunofluorescence
Cells were fixed with 4% paraformaldehyde. After permeabilization with 0.1% Triton 
X-100, cells were incubated with 5% goat serum (Cell Signaling Tecnology®, Danvers, 
MA) and 1% BSA to block non-specific binding. Cells were then stained with the primary 
Ab against human HPSE1 (HPA1, clone HP130) (InSight Biopharmaceuticals Ltd) (1:100 
dilution at 25°C for 2 hours). Cells were then probed with Alexa Fluor 555 goat anti-mouse 
secondary antibody (#44095, 1:500 dilution at 25°C for 2 hours) (Cell Signaling 
technology®). Fluorescent signals were detected using a fluorescence microscope (Olympus 
IX70, Leeds Instruments Inc, Irving, TX). DAPI (BioLegend, San Diego, CA) was used as 
nuclear staining.
RNA isolation and quantitative real-time PCR (qRT-PCR)
For the qRT-PCR, 100 ng of total RNA was used to prepare cDNA (TaqMan One Step PCR 
Master Mix Reagents Kit) (Applied Biosystem, Carlsbad, CA). Specific primers and probes 
Caruana et al. Page 7













that were designed, tested, and standardized by Applied Biosystems for HPSE and p53 were 
used (HPSE: Hs00935036_m1; p53: Hs01034249_m1). The difference in cycle threshold 
values (ΔCT) of HPSE was normalized to the ΔCT of GAPDH (Glyceraldehude-3-phospate 
dehydrogenase, Hs99999905_m1), and the fold-change in expression was expressed relative 
to CD14+ monocytes, considered as a positive control while mesemchymal stem cells were 
used as a negative control. For p53 mRNA quantification the difference in cycle threshold 
values (ΔCT) of p53 was normalized to the ΔCT of GAPDH (Glyceraldehyde-3-phospate 
dehydrogenase, Hs99999905_m1), and the fold-change in expression was expressed relative 
to FI-T.
Enzyme-linked immunosorbent assay (ELISA)
Cytokine release by LTE-T in response to stimulation with GD2+ LAN-1 cells was analyzed 
using IFN-γ and IL-2 specific ELISAs (R&D Systems, Minneapolis, MN). HPSE activity 
was measured using a heparan sulfate (HS) degrading enzyme assay kit (Takara Bio Inc, 
Otsu, Shiga, Japan). HPSE activity was measured in supernatants collected at different time 
point of culture of T lymphocytes. At day 4 and 14 of culture, T cells were collected, 
washed and re-suspended in fresh media. As basal level of HPSE release we used non-
activated T cells rested for 48–72 hours in media. Supernatant from CD14+ monocytes and 
tumor cell lines were used as positive control. HPSE activity was determined as the inverse 
of decrease in absorbance as previously described32, 33. T-cell and tumor cell supernatants 
were analysed in triplicate.
Multiplex for metallo-proteases (MMPs)
Analysis of MMPs was performed using Milliplex Map kit panel 1 and 2 (Millipore) 
following the manufacturer’s instructions. In particular, FI-T cells were activated with 
OKT3 and anti-CD28 mAbs in presence of IL-2 [50 U ml or 2000 U ml] or IL-7 and IL-15 
[10 ng ml and 5 ng ml, respectively]. T cells were fed twice a week. At day 3, 7 and 10 of 
culture, supernatants and T cells were collected and 60 μg sample were tested per well.
p53 chromatin immunoprecipitation (ChIP) assay
LTE-T, CD45RA+ and CD45RO+ T cells were collected and fixed with formaldehyde 
(Merck, Darmstadt, Germany) to a final concentration of 1%. Fixation proceeded at room 
temperature for 10 min and was stopped by the addition of glycine to a final concentration 
of 0.125 mol l. The cells were then washed twice with cold PBS. Pellets were resuspended 
in 350 μl of lysis buffer and protease inhibitors mixture (Active Motif, Carlsbad, CA), 
washed and resuspended in 350 μl of optimized ChIP lysis buffer and protease inhibitors 
mixture (0.5% SDS, 10mM EDTA, 0.5 mM EGTA and 50 mM Tris-HCl, pH 8) and 
sonicated into chromatin fragments of an average length of 500 bp, as determined 
empirically by agarose gel electrophoresis of fragmented chromatin samples. Chromatin was 
kept at −80°C. The chromatin solution was incubated with a p53-specific antibody that 
recognizes the full-length human protein (FL393, Santa Cruz) at 4°C overnight with 
rotation. The immunoprecipitation was performed using Chip-IT® Express kit (Active 
Motif, Carlsbad, CA) following the manufacturer’s instructions. Amplifications (37 cycles) 
were performed using specific primers (Supplementary Figure 11), yielding PCR products ≈ 
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200 bp in length (location of primers relatively to the origin of the promoter is indicated in 
parentheses after each primer pair). PCR products were separated by 1.5% agarose 
electrophoresis in Tris-borate-EDTA buffer and stained with ethidium bromide.
Retroviral constructs, transient transfection and transduction of T lymphocytes
HPSE cDNA (accession number NM-006665) was cloned into the SFG retroviral backbone 
that also encodes the GFP [SFG.HPSE(I)GFP] (Supplementary Fig. 12). The construct for 
the GD2-specific CAR containing the CD28, OX40 and ζ endodomains was previously 
described (SFG.CAR)34. We then generated a bicistronic vector to co-express the HPSE and 
CAR-GD2 using an IRES [SFG.CAR(I)HPSE] (Supplementary Fig. 12). The retroviral 
vector encoding the fusion protein GFP-firefly luciferase (GFP.FFLuc) for in vivo imaging 
of T cells and CD19-specific and CSPG4-specific CARs were previously described35. 
Transient retroviral supernatant was produced as previously described35. A specific inhibitor 
of HPSE, Roneparstat (SST0001) (a chemically modified heparin 100Na,Ro-H, property of 
Sigma-tau Research Switzerland S.A.) (3 μg ml)13, 36, 37, was added to the media during the 
virus preparation to increase its titer. Activated T lymphocytes were then transduced with 
retroviral supernatants using retronectin-coated plates (Takara Bio Inc, Shiga, Japan). After 
removal from the retronectin plates, T-cell lines were maintained in complete T-cell medium 
in a humidified atmosphere containing 5% CO2 at 37°C in the presence of IL-2 (50 U mL) 
for 2 weeks.
Flow cytometry
We performed flow cytometry analysis using the following Abs: CD45, CD56, CD8, CD4, 
CD3, CD45RA, CD45RO, CD62L, 7AAD and Annexin V (all from Becton Dickinson, San 
Jose, CA) and CCR7 (from E&D) conjugated with FITC, PE, PerCP or APC fluorochromes. 
Expression of GD2 and CSPG4 antigens on tumor cell lines was assesed with anti-GD2 
(clone 14.g2a, BD) and anti-CSPG4 (Clone 1E6.4, Miltenyi-Biotech), respectively. The 
expression of GD2-specific CAR was detected using a specific anti-idiotype antibody (1A7). 
Samples were analyzed with a BD FACScalibur system equipped with the filter set for 
quadruple fluorescence signals and the CellQuest software (BD Biosciences). For each 
sample we analyzed a minimum of 10,000 events.
Chromium-release assay
The cytotoxic activity of T cells was evaluated using a standard 6-hour 51Cr-release assay.
Xenogenic mouse models
We used NSG mouse model to assess the in vivo antitumor effect of control and transduced 
T cells. All mouse experiments were approved by Institutional Animal Care and Use 
Committee of Baylor College of Medicine. Eight-10 week old NSG mice (Jackson Lab, Bar 
Harbor, Maine) were injected i.p. with either CHLA-255 or LAN-1 neuroblastoma cells 
(GD2+) (2.5 × 106) or SENMA melanoma cells (CSPG4+) (5×105) resuspended in Matrigel 
(BD Biosciences). These tumor cell lines were labelled with Firefly luciferase. Ten-12 days 
after neuroblastoma inoculation and 2 days after melanoma inoculation, T cells were 
injected i.p. (2 × 107 cells × mouse). No randomization was used. Investigators were not 
Caruana et al. Page 9













blinded, but mice were matched based on the signal of tumor cells before assignment to 
control or treatment groups. Mice were euthanized when signs of discomfort were detected 
by the investigator or as recommended by the veterinarian who monitored the mice three 
times a week. When valuable, tumor growth was also monitored by bioluminescence. For 
the in vivo bio-distribution of T cells, 5 × 106 T cells xmouse labelled with the GFP.FFluc 
vector were infused via tail injection. For in vivo imaging, we used the Xenogen-IVIS 
Imaging System as previously described35. In the orthotopic model26, an inoculum of 106 
CHLA-255 luciferase-transduced tumor cells suspended in 0.1 ml of PBS was surgically 
implanted under the renal capsule of 5–7 week old female mice using a 27-gauge needle. 
CAR+ and CAR(I)HPSE+ T cells were infused i.v. (1–1.5 X 107 × mouse) 7 days later, and 
tumor regression was measured by bioluminescence imaging. By day 10, some mice were 
sacrificed and tumors collected, fixed and stained with anti-human CD3 mAb (A0452, Dako 
North America Inc., Carpinteria, CA). Mice were euthanized when signs of discomfort were 
detected by the investigator or as recommended by the veterinarian who monitored the mice 
three times a week or when luciferase signal reached 7.5 × 107 p sec cm2 sr to investigate 
animal survival. For the lymphoma model mice were infused i.v. with Daudi cells (2 × 106 
cells) labelled with Firefly luciferase. Four days later they were infused i.v. with 107 control 
or CAR+ and CAR(I)HPSE+ T cells specific for the CD19 antigen. Tumor growth was 
measured by bioluminescence imaging. Mice were euthanized when signs of discomfort 
were detected by the investigator or as recommended by the veterinarian who monitored the 
mice twice a week.
Tissue processing and immunohistochemistry
Tissue samples were fixed, processed and stained according to standard procedures. We 
performed Hematoxylin and Eosin staining and labeling of human T cells using polyclonal 
rabbit anti human CD3 mAb (A0452, Dako North America Inc., Carpinteria, CA) and for 
detection we used Dako LSAB + System-HRP (K0679, Dako). Tumors were scored without 
knowledge of the treatment used by the pathologist (Michael M. Ittmann) by counting 
human infiltrating T lymphocytes in 10 high power fields at the edge of the tumor.
Statistical analyses
Unless otherwise noted, data are summarized as mean ± standard deviation (SD). Student t-
test (two-sided) was used to determine statistically significant differences between samples, 
with p value <0.05 indicating a significant difference. When multiple comparison analyses 
were required, statistical significance was evaluated by a repeated measures ANOVA 
followed by a Log-rank (Mantel-Cox) test for multiple comparisons. The mouse survival 
data were analysed using the Kaplan-Meier survival curve and Fisher’s exact test was used 
to measure statistically significant differences. No valuable samples were excluded from the 
analyses. Animals were excluded only in the event of their death after tumor implant but 
before T-cell infusion. Neither randomization nor blinding was done during the in vivo 
study. However, mice were matched based on the tumor signal for control and treatment 
groups before infusion of control or gene modified T cells. To compare the growth of 
tumors over time, bioluminescence signal intensity was log transformed and then compared 
using a two-sample t-test. In contrast, the analysis of the pathologist Michael M. Ittmann, 
aimed at quantifying tumor infiltration by human T cells, was performed in a blind fashion. 
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We estimated the sample size considering the variation and mean of the samples. We tried to 
reach a conclusion using as small a sample size as possible. We estimated the sample size to 
detect a difference in means of 2 standard deviation at the 0.05 level of significance with a 
80% power. Graph generation and statistical analyses were performed using Prism version 
5.0d software (GraphPad, La Jolla, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. LTE-T show reduced invasion of ECM and loss of the enzyme HPSE
(a) ECM invasion assay of CD14+ monocytes (M), freshly isolated T lymphocytes (FI-T), 
briefly activated T cells (BA-T) and long-term ex vivo expanded T cells (LTE-T). 
Monocytes freshly isolated from peripheral blood showed the highest capacity to degrade 
ECM (63% ± 23%). BA-T showed superior invasion of ECM compared to FI-T (*p=0.05). 
Conversely, LTE-T had significantly reduced ability to degrade ECM compared to both BA-
T (**p=0.01) and FI-T (***p=0.022). Data summarize means ± SD of 5 donors. We 
compared all four cell subsets for each donor. (b) Western blot showing the expression of 
HPSE in M, CD4+ and CD8+ T cells at different time points of culture. Data are 
representative of 4 donors. Positive controls are HPSE transfected 293T cells. (c) 
Immunofluorescence staining for HPSE in MCF-7 cells, M, FI-T and LTE-T. Nuclei are 
stained with DAPI and shown in blue, while HPSE is stained with red-fluorescent dye 
(Alexa Fluor 555). Magnification is 20× (50 micron scale bar). (d) qRT-PCR of HPSE in 
CD4+ and CD8+ T cells at different time points of culture. Data summarize means ± SD of 4 
donors. (e) HPSE enzymatic activity assessed in supernatants collected from CD4+ and 
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CD8+ T cells at different time points of culture. Monocytes and tumor cell lines CHLA-255, 
A549 and DU-145 are positive controls. Data summarize means ± SD of 4 donors. In (b), 
(d), (e) the condition “day 15” indicates HPSE expression in LTE-T cultured for 14 days, 
and re-stimulated with immobilized OKT3 and anti-CD28 Abs for 24 hrs to assess whether 
TCR re-stimulation can re-induce HPSE expression. (f) Western blot showing the 
expression of HPSE and full-length p53 protein in T cells before (T=0) and after activation 
with immobilized OKT3 and anti-CD28 Abs for 18 and 72 hrs. Shown are results from 1 
representative of 3 donors. (g) p53 ChIP in LTE-T cultured for 14 days, and (h) in 
CD45RA+ cells before (T=0) and after stimulation with OKT3 and anti-CD28 mAbs 
(T=72h). Input is DNA sonicated but not immunoprecipitated; IgG and p53 are DNA 
immunoprecipitated by the isotype and p53-specific Ab that recognizes the full-length 
protein. Relative quantification was performed comparing the intensities of PCR bands of 
IgG and p53 to input PCR band. For this representative sample relative quantifications are: 
IgG 20% and p53 90% for LTE-T (g); IgG 2% and p53 4% at T=0 and IgG 53% and p53 
100% at T=72h for CD45RA+ cells (h). Shown is 1 representative of 3 donors.
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Figure 2. LTE-T modified to express HPSE show enhanced degradation of ECM
We transduced LTE-T with a retroviral vector encoding HPSE and GFP [HPSE(I)GFP]. (a) 
GFP expression by both CD4+ and CD8+ LTE-T at day 12 – 14 of culture. (b) Western blot 
showing the expression of HPSE in control and transduced LTE-T at day 12 – 14 of culture. 
(c) qRT-PCR for HPSE in control and HPSE(I)GFP+ LTE-T starved in culture from IL-2 for 
3, 7 and 10 days. Data are representative of 2 donors. (d) ECM invasion assay of control and 
HPSE(I)GFP+ LTE-T, with or without selection based on GFP expression. Data summarize 
mean ± SD of 9 donors, *p=0.025; **p<0.001. (e) ECM invasion assay of HPSE-transduced 
LTE-T in the presence or in the absence of the inhibitor, heparin H1. Data summarize mean 
± SD of 4 donors, ***p<0.01.
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Figure 3. LTE-T co-expressing HPSE and GD2-specific CAR retain GD2 specificity and have 
enhanced capacity to degrade ECM
We transduced LTE-T with retroviral vectors encoding either the GD2-specific CAR alone 
(CAR) or both the GD2-specific CAR and HPSE [CAR(I)HPSE]. (a) Flow cytometry 
analysis to detect CAR expression by control and transduced LTE-T. (b) Western blot to 
detect HPSE in control and transduced LTE-T. Data are representative of 5 donors. (c) 
Cytotoxic activity of control, CAR+ and CAR+HPSE+ LTE-T assessed by 51Cr-release 
assay at a 20:1 effector:target ratio. We used LAN-1 and CHLA-255 (GD2+), and Raji 
(GD2−) as target cells. (d) Transduced LTE-T release both IL-2 and IFN-γ in response to 
GD2+ tumor cells. (e) Invasion of ECM by control, CAR+ and CAR+HPSE+ LTE-T. Data in 
(c-e) summarize mean ± SD from 5 donors, *p=0.004. (f,g) We plated control and 
transduced LTE-T in the upper part of either ECM assay or insert assay, and LAN-1-GFP+ 
cells in the lower chamber. After day 3 of culture, we collected cells in the lower chamber to 
quantify CD3+ T cells and GFP+ tumor cells by flow cytometry. (f) illustrates representative 
dot plots, while (g) summarizes mean ± SD of 5 donors, **p=0.009. In all cases we analyzed 
LTE-T by day 12 –14 of culture.
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Figure 4. CAR-GD2+ LTE-T co-expressing HPSE show enhanced tumor infiltration and 
improve overall survival in xenograft tumor models
(a) Kaplan-Meier analysis of mice engrafted i.p. with the tumor cell line CHLA-255 and 
treated i.p. with control, CAR+ and CAR(I)HPSE+ LTE-T. Shown are data from 3 
independent experiments using LTE-T generated from 3 donors; control n=16, CAR n=22, 
CAR(I)HPSE n=26 mice; *p<0.007, **p<0.0001. (b) Kaplan-Meier analysis of mice 
engrafted i.p. with the tumor cell line LAN-1 and treated i.p. with control, CAR+ and 
CAR(I)HPSE+ LTE-T. For these experiments, we generated LTE-T from 2 donors; control 
n=12, CAR n=18, CAR(I)HPSE n=14 mice; *p=0.039, **p<0.0001. (c) Flow cytometry 
analysis of CD3+ T cells detected within the tumor samples. Dot plots are representative of 3 
mice per group from mice infused with LTE-T generated from the same donor. (d) Weight 
of the tumors collected from euthanized mice engrafted with LAN-1 tumor. (e,f) 
Immunohistochemistry showing CD3+ T-cell infiltration in tumors implanted in the kidney 
of mice infused with either CAR+ or CAR-GD2+HPSE+ LTE-T. 100× magnification (e) and 
200× magnification (f) (100 micron scale bar). (g) The graph shows the numbers of 
infiltrating CD3+ T cells per 10 high power fields in tumors collected from mice treated with 
either CAR+ or CAR(I)HPSE+ LTE-T, *p=0.028. (h) Kaplan-Meier analysis of tumor-
bearing mice in the kidney infused i.v. with either CAR+ or CAR(I)HPSE+ LTE-T. For 
these experiments, we generated LTE-T from 2 donors; CAR n=21, CAR(I)HPSE n=21 
mice; *p=0.0006.
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